LOADING
Comparing Merck & Company (MRK) and Pfizer Inc (PFE), both in the Health Care sector. This side-by-side analysis covers price, valuation multiples, profitability, growth, dividends, and risk metrics to help investors evaluate these two stocks.
| Metric | MRK | PFE |
|---|---|---|
| Price | -- | -- |
| Change Today | +0.00% | +0.00% |
| Market Cap | $307.2B | $143.3B |
| P/E Ratio | 36.7 | 19.1 |
| Forward P/E | 48.3 | 8.5 |
| PEG Ratio | 12.06 | 2.94 |
| EPS | $3.55 | $1.31 |
| Revenue Growth (YoY) | 4.9% | 5.4% |
| Profit Margin | 13.6% | 11.8% |
| Return on Equity | 18.9% | 8.3% |
| Dividend Yield | 2.53% | 6.90% |
| Beta | 0.20 | 0.31 |
| 52-Week High | $135.05 | $27.80 |
| 52-Week Low | $75.81 | $21.87 |
| Volume | -- | -- |
Merck & Company is the larger company by market capitalization. Pfizer Inc trades at a lower P/E ratio, suggesting it may offer better value relative to earnings. Pfizer Inc offers a higher dividend yield for income investors. Merck & Company has stronger profit margins. Both stocks should be evaluated in the context of your investment goals, risk tolerance, and portfolio diversification needs.